Lunit

Healthcare AI · Medical Imaging · Oncology

Partnership

Lunit Teams With Microsoft to Scale AI Cancer Diagnostics on Azure

Fine-tuning AI models on local clinical data tackles a core barrier: performance that degrades when deployed across different hospitals.

• Lunit announced a strategic collaboration with Microsoft to accelerate delivery of its AI-powered cancer diagnostics tools globally through Microsoft Azure.
• Lunit (KRX: 328130) is a Seoul-based, publicly traded AI company for cancer diagnostics and precision oncology that acquired breast-screening firm Volpara in 2024, now rebranded Lunit International.
• The companies will co-develop an AI model customization service on Azure that fine-tunes models with site-specific clinical data, aiming to reduce performance variability when AI is deployed across different hospital sites.
• Lunit will also use Microsoft's agentic AI frameworks to build end-to-end clinical workflow automation tools, moving beyond standalone diagnostic point solutions.
• Lunit's cancer-treatment segment, which includes its Lunit SCOPE AI pathology platform, generated only about 2.9 billion won in H1 2026 revenue -- roughly 6% of the company's 45.8 billion won total, with Volpara's imaging SaaS driving most growth.
• The Microsoft tie-up shows Lunit leaning on major cloud platforms to widen distribution while its core AI pathology business still contributes a small share of revenue.